PUNE,
India, April 18, 2024 /PRNewswire/ -- The
report titled "Progressive Familial Intrahepatic
Cholestasis Treatment Market by Drug Type (Cholestyramine,
Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital
Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users -
Global Forecast 2024-2030" is now available on
360iResearch.com's offering, presents an analysis indicating that
the market projected to grow from a size of $113.52 million in 2023 to reach $156.14 million by 2030, at a CAGR of 4.65% over
the forecast period.
"Advancements and Global Initiatives Propel
Progressive Familial Intrahepatic Cholestasis (PFIC) Treatment
Landscape"
Progressive Familial Intrahepatic Cholestasis (PFIC), a group of
rare liver disorders caused by genetic anomalies, disrupts bile
flow, leading to severe liver conditions. Recognizing PFIC's
critical nature, healthcare and regulatory agencies worldwide have
accelerated diagnostic and treatment approaches. Enhanced genetic
screening facilitates prompt intervention, while regulatory bodies,
including the FDA and EMA, streamline approval processes for PFIC
therapies. This effort has stimulated the development of innovative
treatments and made liver transplantation more accessible. Cost
considerations remain a challenge. Across the globe, regions are
taking significant strides, including the Americas, which has
robust healthcare systems and vigorous patient advocacy, driving
awareness and treatment advancements. In the APAC region, countries
such as Japan and Australia possess exemplary healthcare
innovation, providing substantial support for PFIC management.
Europe is at the forefront of PFIC
research, benefitting from the EMA's cohesive policies and
regulatory agility to expedite treatment access. As awareness
grows, even regions with emerging healthcare infrastructures, such
as the Middle East and
Africa, are beginning to ramp up
PFIC recognition and care. This collective global initiative
signifies a hopeful trajectory for PFIC patients, highlighting the
importance of novel treatment options and international cooperation
in overcoming rare liver diseases.
Download Sample Report
@ https://www.360iresearch.com/library/intelligence/progressive-familial-intrahepatic-cholestasis-treatment
"Advocacy Groups Facilitating Change in
Treatment Access and Awareness"
Patient advocacy organizations worldwide play a pivotal role in
enhancing awareness, support, and advancements in treatment. Groups
such as the PFIC Advocacy and Resource Network by the National
Organization for Rare Disorders (NORD) and the American Liver
Foundation are at the forefront of creating supportive communities
for patients and their families, offering education, and funding
research to improve liver health. Australian charity Liver Kids
supports children with liver diseases, emphasizing the need for
robust health policies. These groups are instrumental in fostering
collaborations, fueling research and development, and improving
communication between patients, healthcare systems, and
pharmaceutical entities. Their efforts are crucial in ensuring
patients have access to newly approved treatments, helping to
demystify the complexities of insurance, and providing guidance on
treatment options, ultimately aiming for earlier diagnosis, better
management, and enhanced quality of life for those impacted by
PFIC.
"Innovative Treatments Offer New Hope for
Patients with Progressive Familial Intrahepatic
Cholestasis"
Cholestyramine, a drug traditionally used to lower cholesterol,
is gaining attention for its role in managing progressive familial
intrahepatic cholestasis (PFIC), a rare liver disorder.
Cholestyramine effectively lowers bile acid levels in both the
liver and blood, offering relief from the intense itching often
experienced by patients by binding to bile acids in the intestine
and preventing reabsorption. Additionally, Rifampicin, commonly
used as an antibiotic, treats this symptom by promoting the
elimination of bile acids through the induction of liver enzymes.
However, its use requires careful monitoring due to potential
interactions and side effects. Meanwhile, ursodeoxycholic acid
(UDCA) substitutes harmful bile acids with less toxic ones, helping
to minimize liver damage and enhance bile flow. UDCA's safety and
tolerance levels make it a vital option, though its efficacy may
vary by individual cases regarded as a basis in PFIC treatment.
These advancements in treatment provide much-needed assurance and
relief for those affected by PFIC, representing a forward path in
managing this challenging condition.
Request Analyst Support
@ https://www.360iresearch.com/library/intelligence/progressive-familial-intrahepatic-cholestasis-treatment
"Ipsen Pharma at the Forefront of
Progressive Familial Intrahepatic Cholestasis Treatment Market with
a Strong 15.94% Market Share"
The key players in the Progressive Familial Intrahepatic
Cholestasis Treatment Market include Takeda Pharmaceutical Company
Limited, Ipsen Pharma, Mirum Pharmaceuticals, Inc., Sanofi S.A.,
AbbVie, Inc., and others. These prominent players focus on
strategies such as expansions, acquisitions, joint ventures, and
developing new products to strengthen their market positions.
"Introducing ThinkMi: Revolutionizing
Market Intelligence with AI-Powered Insights for the Progressive
Familial Intrahepatic Cholestasis Treatment Market"
We proudly unveil ThinkMi, a cutting-edge AI product designed to
transform how businesses interact with the Progressive Familial
Intrahepatic Cholestasis Treatment Market. ThinkMi stands out as
your premier market intelligence partner, delivering unparalleled
insights with the power of artificial intelligence. Whether
deciphering market trends or offering actionable intelligence,
ThinkMi is engineered to provide precise, relevant answers to your
most critical business questions. This revolutionary tool is more
than just an information source; it's a strategic asset that
empowers your decision-making with up-to-the-minute data, ensuring
you stay ahead in the fiercely competitive Progressive Familial
Intrahepatic Cholestasis Treatment Market. Embrace the future of
market analysis with ThinkMi, where informed decisions lead to
remarkable growth.
Ask Question to ThinkMi
@ https://app.360iresearch.com/library/intelligence/progressive-familial-intrahepatic-cholestasis-treatment
"Dive into the Progressive Familial
Intrahepatic Cholestasis Treatment Market Landscape: Explore 188
Pages of Insights, 286 Tables, and 22 Figures"
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Progressive Familial Intrahepatic Cholestasis Treatment Market,
by Drug Type
- Progressive Familial Intrahepatic Cholestasis Treatment Market,
by Distribution Channel
- Progressive Familial Intrahepatic Cholestasis Treatment Market,
by End-Users
- Americas Progressive Familial Intrahepatic Cholestasis
Treatment Market
- Asia-Pacific Progressive Familial Intrahepatic Cholestasis
Treatment Market
- Europe, Middle East & Africa Progressive Familial
Intrahepatic Cholestasis Treatment Market
- Competitive Landscape
- Competitive Portfolio
Inquire Before Buying
@ https://www.360iresearch.com/library/intelligence/progressive-familial-intrahepatic-cholestasis-treatment
Related Reports:
- Rare Disease Diagnostics Market - Global Forecast
2024-2030
- Cancer Gene Therapy Market - Global Forecast 2024-2030
- Liver Diseases Therapeutics Market - Global Forecast
2024-2030
About 360iResearch
Founded in 2017, 360iResearch is a market research and business
consulting company headquartered in India, with clients and focus markets spanning
the globe.
We are a dynamic, nimble company that believes in carving
ambitious, purposeful goals and achieving them with the backing of
our greatest asset — our people.
Quick on our feet, we have our ear to the ground when it comes
to market intelligence and volatility. Our market intelligence is
diligent, real-time and tailored to your needs, and arms you with
all the insight that empowers strategic decision-making.
Our clientele encompasses about 80% of the Fortune Global 500,
and leading consulting and research companies and academic
institutions that rely on our expertise in compiling data in niche
markets. Our meta-insights are intelligent, impactful and infinite,
and translate into actionable data that support your quest for
enhanced profitability, tapping into niche markets, and exploring
new revenue opportunities.
Contact 360iResearch
Mr. Ketan Rohom
360iResearch Private Limited,
Office No. 519, Nyati Empress,
Opposite Phoenix Market City,
Vimannagar, Pune, Maharashtra,
India - 411014.
Email: sales@360iresearch.com
USA: +1-530-264-8485
India: +91-922-607-7550
To learn more, visit 360iresearch.com or follow us on LinkedIn,
Twitter, and Facebook.
Logo:
https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/progressive-familial-intrahepatic-cholestasis-treatment-market-projected-to-reach-156-14-million-by-2030---exclusive-report-by-360iresearch-302119664.html
SOURCE 360iResearch